- Pro-Cure has actively recruited a strong and experienced executive management team, able to draw upon long track records of success in the biotechnology and pharmaceutical fields. Management is supported by a Board highly experienced in the development of businesses in biotechnology. Brief biographical details for senior members of Management include:
Mick McLean, CEO
- 20+ years in the biotechnology industry with leadership roles in the US, UK and EU
- Former President of Avecia Biotechnology (Boston, MA) and CEO of Oligovax (Paris); currently Chairman for Link Technologies Limited (Glasgow)
- Track record of leading organisations through change and rapid growth, negotiating deals and raising money
- Professor of Molecular Biology (University of York) and Director of the YCR Cancer Research Unit
- Past Chairman of the European Society for Basic Urological Research and the British Prostate Group, member of the MRC College of Experts
- Coordinator for, or participant in, EU collaborative projects in prostate cancer totalling >€20m
Steve Holmes, CTO
- 20+ years in biotech and Pharma with leadership roles at SmithKline, Oxford GlycoSystems, Domantis and GlaxoSmithKline
- Antibody lead discovery, preclinical development and target discovery expertise
- mAb and dAb experience, discovered pascolizumab and mepolizumab
John Knights, CFO
- Highly experienced Finance Director and business professional in the telecommunications sector, with responsibility for collection of >£15bn in revenue
- Former FD of BT’s Business Division (including responsibility for O2 and Yell), and CEO for Argensys Limited
- Track record of developing and implementing effective business processes
